In previous studies, concurrent pathogenic mutations in TP53/STK11/KEAP1 may be positive/negative factors of treatment efficacy and survival in KRAS‐mutant NSCLC patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.